PE Tech Report


Like this article?

Sign up to our free newsletter

LUCA Science raises JPY3.86bn in oversubscribed Series B financing, co-led by Fast Track Initiative, DCI Partners, and 4BIO Capital

LUCA Science, a global innovator in the development of a novel class of mitochondria biopharmaceutical agents, has closed a JPY3.86 billion ($30.3 million) oversubscribed Series B financing.

The round was co-led by DCI Partners, 4BIO Capital and existing investor Fast Track Initiative and supported by an international syndicate of existing investors including Remiges Ventures and Nippon Venture Capital Co, and new investors including Nissay Capital, Asahi Kasei Pharma, QB Capital/NCB Venture Capital and SMBC Venture Capital.

LUCA Science is pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. 

Following the closing of the financing, Philippe Fauchet of 4BIO Capital, Tai Harada of Fast Track Initiative, and Shuntaro Kodama of DCI Partners will join LUCA Science’s Board of Directors.

Like this article? Sign up to our free newsletter